SRGN (Serglycin)
Proteoglycan Core Protein Involved in Immune Regulation and Tumor Biology
Gene Information Card
| Symbol | SRGN |
|---|---|
| Full Name | Serglycin |
| Gene Type | protein-coding |
| Chromosomal Location | 10q22.1 |
| NCBI Gene ID | 5552 ncbi.nlm.nih.gov/gene/5552 |
| Ensembl ID | ENSG00000122862 |
| UniProt ID | P10124 |
| OMIM ID | 177040 |
| HGNC ID | 11210 |
| Aliases | PRG1, PRG, PPG, serglycin proteoglycan |
Description
SRGN encodes serglycin, a proteoglycan core protein that is stored in secretory granules of hematopoietic cells. It binds to various proteases and growth factors, playing a key role in immune cell function, inflammation, and tumor progression. The gene is located on chromosome 10q22.1 and is primarily expressed in bone marrow, lymphoid tissues, and certain cancer cell lines.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Multiple Myeloma | Overexpression of SRGN promotes tumor cell survival and drug resistance via interaction with proteases and cytokines. | NCBI Gene, COSMIC |
| Breast Cancer | SRGN expression correlates with metastasis and poor prognosis; serglycin enhances invasive capacity. | NCBI Gene, COSMIC |
| Inflammatory Disorders | Serglycin modulates immune cell degranulation and cytokine release, implicated in rheumatoid arthritis and asthma. | NCBI Gene, OMIM |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Bone Marrow | 112.5 | High |
| Lymph Node | 78.3 | High |
| Spleen | 65.1 | High |
| Lung | 12.4 | Low |
| Liver | 5.2 | Not detected |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| K-562 (leukemia) | 89.7 | High expression |
| HeLa (cervical) | 23.1 | Moderate expression |
| MCF7 (breast) | 45.6 | Moderate expression |
| A549 (lung) | 8.9 | Low expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1A>G (p.Met1?) | missense | <0.1% | Potential loss of start codon; uncertain significance |
| c.214C>T (p.Arg72Cys) | missense | <0.1% | Reported in COSMIC; functional impact unknown |
| c.367G>A (p.Gly123Ser) | missense | <0.1% | Observed in cancer samples; no known pathogenicity |
Mutation functional classification
Loss of Function (LOF)
No confirmed loss-of-function mutations reported in ClinVar or COSMIC.
Gain of Function (GOF)
No confirmed gain-of-function mutations reported.
Dominant Negative (DN)
No evidence of dominant-negative effects.
View complete mutation data：
Gene Ontology (GO)
| • extracellular region (GO:0005576) | • secretory granule (GO:0030141) |
| • glycosaminoglycan binding (GO:0005539) | • protease binding (GO:0002020) |
| • extracellular structure organization (GO:0043062) |
Pathways
• Proteoglycan biosynthesis (Reactome: R-HSA-1638091)
• Degradation of the extracellular matrix (Reactome: R-HSA-1474228)
• Innate immune system (Reactome: R-HSA-168249)
Protein Summary
Serglycin is a small proteoglycan core protein (17.6 kDa) that is heavily glycosylated with chondroitin sulfate or heparin sulfate chains. It is stored in secretory granules of hematopoietic cells and released upon activation, where it binds to proteases (e.g., granzyme B, tryptase) and growth factors, regulating their activity. Serglycin is essential for proper granule function in mast cells, neutrophils, and cytotoxic T lymphocytes, and its dysregulation is linked to cancer progression and inflammatory diseases.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| SRGN Knockout HEK293 Cell Line | EDJ-KQ5526 | Human | 5552 | Details Get a Quote |
| SRGN Knockout A-549 Cell Line | EDJ-KQ28770 | Human | 5552 | Details Get a Quote |
| SRGN Knockout HeLa Cell Line | EDJ-KQ28771 | Human | 5552 | Details Get a Quote |
| SRGN Knockout HCT 116 Cell Line | EDJ-KQ71170 | Human | 5552 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
